VarmX: Funding, Investors & Team (Sep 2026)
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
VarmX has raised $37.1M across 1 funding round on record, the most recent a Series B of $37.1M announced in May 2023.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
VarmX Company Profile and Key Stats
Latest funding round on record: May 2023.
VarmX Funding Rounds
VarmX Founders and Leadership Team
No contact details are on record for this team yet.
VarmX Funding Compared to Other Health Care Startups
VarmX's latest round of $37.1M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like VarmX in Health Care and Leiden
Companies Similar to VarmX
The most cutting-edge polymer-based platform of restorative cardiovascular devices was created by Xeltis.…
Vitestro revolutionizes the way patients are cared for by introducing independent blood-drawing technology.
ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and…
Speaklee is a company that utilizes AI technology to create a speech assistant tool for children who have…
CardiacBooster is a company in the medical field that creates percutaneous devices to assist the left…
Plasmacure offers a patented cold plasma solution designed to heal chronic wounds. They provide services in…
Hy2Care® is a company that originated from the MIRA Institute at the University Twente in the Netherlands, a…
Platos Health is a technology startup dedicated to increasing access to preventive healthcare. Our current…
AVIGI Therapeutics is leading the way in creating new drugs through a rational approach that combines…
Sirius medical helps in improving healthcare for cancer patients by developing medical devices that helps in…
PROBLEM Insufficient treatment of vulnerable plaque in the coronary arteries lead to costly and health…
VarmX Funding FAQs
What does VarmX do?
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
How much funding has VarmX raised?
VarmX has raised $37.1M across 1 round on record. The most recent is a Series B of $37.1M announced in May 2023.
When did VarmX last raise funding?
VarmX's most recent funding round on record is a Series B of $37.1M, announced in May 2023.
Who is the CEO of VarmX?
Jan Ohrstrom is listed as CEO at VarmX.
Where is VarmX headquartered?
VarmX is based in Leiden, Zuid-Holland, Netherlands.
How many employees does VarmX have?
VarmX is in the 1-10 employee band.
How does VarmX's funding compare to other Health Care startups?
VarmX's latest round of $37.1M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's VarmX Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for VarmX is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.